RxDoctor Payments Data

Jenna Oates

Family · Dothan, ALNPI 1013304468

Payments from drug & device makers

$10,893in general payments, 2019–2025

Across 569 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Incyte Corporation$701
  • Bristol Myers Squibb$612
  • Johnson & Johnson$525
  • Amgen$470
  • Pfizer$429
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,69398%
  • Education$2002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis64$1,197
Incyte Corporation36$701
Bristol Myers Squibb30$612
Johnson & Johnson32$525
Amgen31$470
Pfizer30$429
Genentech USA, Inc.19$380
E.r. Squibb & Sons, L.L.C.19$372
Regeneron Healthcare Solutions, Inc.15$349
Takeda Pharmaceuticals U.S.A., Inc.15$340
Merck16$314
Lilly USA, LLC18$301
AbbVie11$273
Exelixis Inc.15$261
Sanofi11$257
Astellas Pharma US Inc7$232
AstraZeneca13$223
Beigene USA, Inc.11$187
Array Biopharma Inc14$186
Eisai Inc.10$184
Daiichi Sankyo Inc.9$182
Deciphera Pharmaceuticals Inc.8$168
Eagle Pharmaceuticals, Inc.3$155
Ipsen Biopharmaceuticals, Inc7$144
Myriad Genetic Laboratories, Inc.3$141
Pharmaessentia USA Corporation5$137
Pharmacyclics LLC, An Abbvie Company7$127
Gilead(2 entities)5$109
Seagen Inc.7$105
Bayer5$105
AVEO Pharmaceuticals, Inc.5$100
GSK6$98
Coherus Oncology, Inc.4$94
Boehringer Ingelheim4$86
Sumitomo Pharma America, Inc.5$73
Beone Medicines USA, Inc.3$69
Karyopharm Therapeutics Inc.4$63
Myovant Sciences Inc.4$61
Spectrum Pharmaceuticals Inc.3$59
Puma Biotechnology, Inc.3$56
Sobi, Inc2$55
Servier Pharmaceuticals LLC3$55
Pharmacosmos Therapeutics Inc.3$54
Blueprint Medicines Corporation3$52
Genmab U.S., Inc.3$51
EMD Serono, Inc.3$51
Jazz Pharmaceuticals Inc.2$45
Tersera Therapeutics LLC2$45
Agios Pharmaceuticals, Inc.2$42
Fennec Pharmaceuticals, Inc.2$40
Acceleron Pharma, Inc.2$39
G1 Therapeutics, Inc.2$39
Progenics Pharmaceuticals, Inc.2$34
Dendreon Pharmaceuticals LLC2$34
HEMA Biologics, LLC2$34
Acrotech Biopharma Inc.2$32
Taiho Oncology, Inc.2$31
Morphosys, US Inc.2$30
Immunogen, Inc.1$25
Geron Corporation1$25

How this compares

$10,893 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$49,464
Medicare patients
296
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban25$14,352
Anastrozole82$2,241
Letrozole28$559
Tamoxifen Citrate13$541
Prochlorperazine Maleate15$332
Hydroxyurea15$190
Ondansetron Hcl11$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$525$14,35225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →